Insulet develops tubeless, wearable automated insulin delivery systems (Omnipod) for diabetes management, serving over 600,000 customers in 25 countries as a NASDAQ-listed medical device company.
Insulet Corporation designs and manufactures tubeless, wearable automated insulin delivery systems, a category-defining line of medical devices sold under the Omnipod name. Founded in 2000, the company is publicly traded on NASDAQ under the ticker PODD and reported revenue of $2.1 billion, having grown from a personal mission - a founder's napkin sketch conceived to spare his son daily multiple insulin injections - into a publicly listed medical device innovator.
Its flagship products reflect a string of engineering firsts. Omnipod 5 is the world's first tubeless automated insulin delivery system controlled by a smartphone, and it is the number-one prescribed automated insulin delivery system in the United States. The broader Omnipod platform serves more than 600,000 customers across 25 countries, with a presence spanning North America, Europe, the Middle East and Asia Pacific. The underlying technical work spans tubeless pump technology, wearable and connected health devices, smartphone-controlled medical systems, and diabetes management technology.
Insulet operates at the intersection of diabetes care, drug delivery and healthcare technology, where regulatory rigour, reliability and patient outcomes set the standard. The company describes a purpose-driven culture rooted in continuous innovation and a commitment to sustainable, responsible growth, with a close relationship to the patient community it serves - customers are known as Podders.
